Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

ENDOCRINE > Thyroid Guidelines > Flashcards

Thyroid Guidelines Flashcards

1
Q

How to administer MMI during RAI treatment

A

Discontinue 2-3 days prior yo therapy and resume 3-7 d after RAI and taper

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

RAI dose for graves

A

10-15 mCi

370-555 MBq

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

When to follow up RAI therapg

A

1-2 mos
Ft4
Tital t3
Tsh

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

When to consider readmi nistratoon of RAI

A

Hyperthyroudidm persistent after 6 mongths

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Recommended dose of MMI

A

If FT4 > ULN

1-1.5 5-10
1.5-2 10-20
2-3 30-40

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Recommended initial and maintenance dose of MMI

A

Initial 10-30daily

Maintenance 5-10 daily

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

In calculating dose for RAI what should gland weight be multiplied to

A

50-200 over 24 h % amdinistered activity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Higher doses of ATD armin combindwd with L thyroxine

A

Block and repalce therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

KI and ATD dose

A

38 mg KI wifh 15 mg MMI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Vasculitis in ATDs

A

Anca positive vasculitus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

When to treat subclinical hyperthyroidism

A 
TSH <0.1 
Individuals > 65 y age 
(+) cardiac risk factos 
Heart diaease or osteoporosis
Post menopausal women not on estrogen
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Elecations in transaminases 3x above upper limit of normal occur ___ % jn px taking ptu

A

4%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Duration of MMI as primary therapy for GD

A

12-18 mos

Then discontinued if TSH and TRAB are normal at that time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Remission in gaves

A

1 yr after Dc thyroid therapy N tsh ft4 total t3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Discsharging post op grgave spx with Lt4

A

0.8-1.6 ug/kg

Remeasure 6-8 weeks post op

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Burch wartofsky score to start treatment

A

> 45

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

ATA high risk histopath

A 
Macroscopic invasion of tumor
Kncomplete resection of the tumor
Distant meta 
Post op Tg distant mets 
Pathologic N1 wuth LN > 3 cn 
Follicular thyroid Ca with extensive vascular invasion >4 foci
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Define biochemical incomplete respinse to theraoy

A

Nonstimulated Tg values of > 1 ng/mL

TSH stumulates valuze > 10 biochemical i complete response to therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Intermediate risk TSH goal

A

0.1-0.5 mU/L

20
Q

Low risk tsh goal

A

If nonstimulated Tg <0.2 ex response
Tsh 0.5-2

If nonsti Tg >0.2
Tab 0.1-0.5

21
Q

Type 1 AIT

A

ipdine induxed form of hyperthyroidism

Due to 37% I of amiodarone

22
Q

AIT 2

A

Destruxtive thyroiditis

23
Q

Suggested dose of corticosteeoida in AIT 2

A

Prednisone 40 mg OD

24
Q

Target in pregnancy treatment of hypertheoidism

A

Maintajn maternal TT4/ FT4 just aboce the upper limit of normal

25
Q

Biochemical goal in treating hypothyroidism in pregnant women

A

TSH in the lower half of the trimester specific range

When not available TSH less than 2.5

26
Q

UTZ features of Ln predictive of malignant involvement

A 
Microcalcifications
Cystic aspect 
Peripheral vasculRity 
Huperechogwnicity
Round shape
27
Q

High suspicion thyroid nodule % malignancy

A

70-90%

28
Q

Intermediate risk nodule

A

10-20% malignancy

29
Q

Cancer risk low suspicion nodule

A

5-10%

30
Q

Cancer risk

Very low suspicion nodule

A

<5%

31
Q

Size to do biopsy high and int risk

A

> 1 cm

32
Q

Size to do hiopsy low suspicion

A

1.5 cm

33
Q

Size to do biopsy

Vey low suspicion

A

2 cm or more

34
Q

FNAB risk for malignancy

Benign

A

0-3

35
Q

FNAB risk for malignancy

Follicular neoplasm

A

15-30%

36
Q

ATA low risk

Post op

A 
PTC WITH:
- no mets
- all macroscopic tumor resected
- no tumor invasion 
- tumor does not have aggressive histology
-
37
Q

High suspicion thyroid nodule % malignancy

A

70-90%

38
Q

Intermediate risk nodule

A

10-20% malignancy

39
Q

Cancer risk low suspicion nodule

A

5-10%

40
Q

Cancer risk

Very low suspicion nodule

A

<5%

41
Q

Size to do biopsy high and int risk

A

> 1 cm

42
Q

Size to do hiopsy low suspicion

A

1.5 cm

43
Q

Size to do biopsy

Vey low suspicion

A

2 cm or more

44
Q

FNAB risk for malignancy

Benign

A

0-3

45
Q

FNAB risk for malignancy

Follicular neoplasm

A

15-30%

46
Q

ATA low risk

Post op

A 
PTC WITH:
- no mets
- all macroscopic tumor resected
- no tumor invasion 
- tumor does not have aggressive histology
-

ENDOCRINE (12 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions